Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GTHPNASDAQ:LYRAOTCMKTS:VYCONASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTHPGuided Therapeutics$0.23$0.13$0.06▼$0.23$18.15M-0.113,384 shs5,897 shsLYRALyra Therapeutics$10.68+3.9%$8.25$3.81▼$37.50$14.15M-0.01187,997 shs116,783 shsVYCOVycor Medical$0.12$0.12$0.03▼$0.50$3.84M-0.423,641 shs10 shsXAIRBeyond Air$0.20-29.0%$0.20$0.16▼$1.49$17.47M0.231.50 million shs10.73 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTHPGuided Therapeutics0.00%+15.00%+84.00%+130.00%+53.33%LYRALyra Therapeutics+3.89%-20.89%+99.81%+28.21%-17.47%VYCOVycor Medical0.00%-2.44%-4.41%+77.54%+15.00%XAIRBeyond Air-29.02%+1.15%+6.64%-23.34%-83.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGTHPGuided TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALYRALyra Therapeutics3.0993 of 5 stars3.24.00.00.04.01.70.6VYCOVycor MedicalN/AN/AN/AN/AN/AN/AN/AN/AXAIRBeyond Air4.2351 of 5 stars3.54.00.03.52.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTHPGuided Therapeutics 0.00N/AN/AN/ALYRALyra Therapeutics 2.33Hold$100.00836.33% UpsideVYCOVycor Medical 0.00N/AN/AN/AXAIRBeyond Air 3.00Buy$1.50641.47% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTHPGuided Therapeutics$10K1,814.93N/AN/A($0.12) per share-1.92LYRALyra Therapeutics$1.53M9.28N/AN/A$8.86 per share1.21VYCOVycor Medical$1.59M2.42N/AN/A($0.11) per share-1.05XAIRBeyond Air$3.70M4.72N/AN/A$0.75 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTHPGuided Therapeutics-$2.42M-$0.05N/A∞N/AN/AN/A-197.32%8/12/2025 (Estimated)LYRALyra Therapeutics-$93.43M-$60.50N/AN/AN/A-6,711.39%-295.52%-66.95%8/12/2025 (Estimated)VYCOVycor Medical-$110KN/A0.00∞N/A-6.86%N/A-11.44%8/11/2025 (Estimated)XAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,258.46%-213.97%-104.66%8/5/2025 (Estimated)Latest VYCO, XAIR, LYRA, and GTHP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million5/15/2025Q1 2025GTHPGuided TherapeuticsN/A-$0.01N/A-$0.01N/AN/A5/15/2025Q1 2025VYCOVycor MedicalN/A-$0.01N/A-$0.01N/A$0.44 million5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 million3/31/2025Q4 2024GTHPGuided TherapeuticsN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTHPGuided TherapeuticsN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AVYCOVycor MedicalN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTHPGuided TherapeuticsN/A0.140.03LYRALyra TherapeuticsN/A2.962.96VYCOVycor MedicalN/A0.130.09XAIRBeyond AirN/A3.563.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTHPGuided Therapeutics9.69%LYRALyra Therapeutics95.62%VYCOVycor MedicalN/AXAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipGTHPGuided Therapeutics66.83%LYRALyra Therapeutics3.25%VYCOVycor Medical7.03%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGTHPGuided Therapeutics578.91 million26.18 millionNot OptionableLYRALyra Therapeutics501.33 million1.28 millionOptionableVYCOVycor Medical633.42 million31.07 millionNot OptionableXAIRBeyond Air7086.37 million69.61 millionOptionableVYCO, XAIR, LYRA, and GTHP HeadlinesRecent News About These CompaniesBeyond Air posts narrower-than-feared Q4 loss, shares surge 15%June 18 at 6:48 PM | investing.comBeyond Air Reports Strong Revenue Growth and Strategic AdvancesJune 18 at 12:26 AM | tipranks.comBeyond Air, Inc. (XAIR) Q4 2025 Earnings Call TranscriptJune 17 at 10:05 PM | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17 at 7:00 PM | finance.yahoo.comBeyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue EstimatesJune 17 at 6:16 PM | zacks.comBeyond Air Stock Dips After Mixed Q4 Results: Here's What To KnowJune 17 at 4:32 PM | benzinga.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17 at 4:15 PM | globenewswire.comBeyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide GeneratorJune 16 at 8:27 AM | quiverquant.comBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHJune 16 at 8:00 AM | globenewswire.comBeyond Air (XAIR) to Release Quarterly Earnings on TuesdayJune 10, 2025 | americanbankingnews.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comBeyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung InfectionsApril 24, 2025 | quiverquant.comBeyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 23, 2025 | finanznachrichten.deNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYCO, XAIR, LYRA, and GTHP Company DescriptionsGuided Therapeutics OTCMKTS:GTHP$0.23 0.00 (0.00%) As of 06/18/2025 03:49 PM EasternGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Lyra Therapeutics NASDAQ:LYRA$10.68 +0.40 (+3.89%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$10.81 +0.13 (+1.25%) As of 06/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Vycor Medical OTCMKTS:VYCO$0.12 0.00 (0.00%) As of 06/18/2025Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.Beyond Air NASDAQ:XAIR$0.20 -0.08 (-29.02%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.21 +0.01 (+4.30%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
